therapy | Audio Medica – Medical Audio News Interviews & Podcasts

“Total Therapy” Possible Cure For Multiple Myeloma?+

26th February 2008

Bart Barlogie

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
BART BARLOGIE, University of Arkansas, Little Rock
A treatment known as “total therapy” could cure many patients with multiple myeloma, conference-goers have just heard. The targeted

…

Read More+

Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma+

26th February 2008

Martin Dreyling

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He

…

Read More+

Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon+

25th February 2008

Kenneth Anderson

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston
Multiple myeloma may soon be considered a chronic disease with cure on the horizon, thanks to an array of novel

…

Read More+

Gastrointestinal Cancers: Progress with Targeted Therapies+

27th January 2008

Robert Mayer

ROBERT MAYER, Dana-Farber Cancer Institute, Boston
One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and

…

Read More+

New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer+

15th December 2007

Jose Baselga

JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and

…

Read More+

Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML+

10th December 2007

richard stone Live Report from ASH:<br />Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML” src=”http://www.audiomedica.com/img/asco/071209/richard_stone.jpg” /<br /> Richard Stone </div>
</p>
</div>
<div>
<div>
<strong> RICHARD STONE, Dana-Farber Cancer Institute, Boston<br />
GEORGE CANELLOS, Dana-Farber Cancer Institute</strong><br />
New data shows that dasatinib is giving durable responses in patients with chronic phase </div>
</div>
<p>…</p></div>
<!--END .post-content -->

</div>

<a class=

Read More+

No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia+

9th December 2007

Zakari Aliyu

REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
ZAKARI ALIYU, Howard University, Washington DC
Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with

…

Read More+

Protective Cardiovascular Benefit for Women on HRT For Natural Menopause+

6th November 2007

georg sopko Protective Cardiovascular Benefit for Women on HRT For Natural Menopause

George Sopko

REFERENCE: Abstract 3771, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
GEORGE SOPKO, National Heart, Lung And Blood Institute, Bethesda, Maryland
COMMENT: JENNIFER MIERES, New York University
A new study presented

…

Read More+

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?+

6th November 2007

Gregg Stone

REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone

…

Read More+

Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study+

6th November 2007

Uwe Zeymer

REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients

…

Read More+

Eptifibatide After PCI: Brief Infusion Is Just As Good+

5th November 2007

Anthony Fung

REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
ANTHONY FUNG, University of British Columbia, Vancouver
Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as

…

Read More+

Stable Angina: Add PCI To Medical Therapy If Guided by SPECT-Detected Ischemia? COURAGE Nuclear Sub-Study Results+

5th November 2007

Leslee Shaw
daniel jones Stable Angina: Add PCI To Medical Therapy If Guided by SPECT Detected Ischemia? COURAGE Nuclear Sub Study Results

Daniel Jones

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LESLEE SHAW, Emory University, Atlanta
COMMENT: DANIEL JONES, AHA President, University of Mississippi, Jackson
Some patients with stable

…

Read More+

13 posts remaining + Load More